Lewis H. Bender to Discuss Factors of Inflammation in Chronic Diseases of
WALTHAM, Mass., June 10 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI), announced today that Lewis H. Bender, Chief Executive Officer, will make a corporate presentation at the BIO Business Forum during the 2008 BIO International Convention in San Diego, CA. The presentation will be held on Wednesday, June 18 at 1:30 PM PDT in room 5A. The presentation will not be webcast. Mr. Bender will be available for one-on-one meetings throughout the conference. For more information, please visit http://www.bio2008.org .
WHO: Lewis H. Bender, Chief Executive Officer of Interleukin Genetics
WHERE: BIO International Convention, San Diego Convention Center, San Diego, CA
WHEN: Wednesday, June 18 at 1:30 PM PDT
WHAT: Long before anyone was using the words "personalized healthcare" and "personalized medicine," Interleukin Genetics was focused on harnessing knowledge about the genetics of a key bodily defense system - inflammation - and developing ways to modulate that system that would promote wellness. Interleukin Genetics will use the BIO Business Forum to discuss the company's proprietary intellectual property, partnering, business model, commercialized genetic tests, and recent milestones.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI), is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin, its products and ongoing programs, please visit http://www.ilgenetics.com .
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
|SOURCE Interleukin Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved